Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2023

Open Access 07-07-2023 | SCLC | CLINICAL GUIDES IN ONCOLOGY

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

Authors: Rosario García-Campelo, Ivana Sullivan, Edurne Arriola, Amelia Insa, Oscar Juan Vidal, Patricia Cruz-Castellanos, Teresa Morán, Noemí Reguart, Jon Zugazagoitia, Manuel Dómine

Published in: Clinical and Translational Oncology | Issue 9/2023

Login to get access

Abstract

Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum–etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.
Literature
1.
2.
3.
4.
Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM Jr, Deming RL, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North central cancer treatment group trials. Cancer. 2009;115(12):2721–31.PubMedCrossRef
5.
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–25.PubMedPubMedCentralCrossRef
6.
Franco F, Carcereny E, Guirado M, Ortega AL, Lopez-Castro R, Rodriguez-Abreu D, et al. Epidemiology, treatment, and survival in small cell lung cancer in Spain: data from the thoracic tumor registry. PLoS One. 2021;16(6): e0251761.PubMedPubMedCentralCrossRef
7.
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2): 100408.PubMedPubMedCentralCrossRef
8.
Ou S-HI, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol. 2009;4(1):37–43.PubMedCrossRef
9.
Sivakumar S, Moore JA, Montesion M, Sharaf R, Lin DI, Fleishmann Z, et al. Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation. bioRxiv. 2022;9:1.
10.
Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44.PubMedCrossRef
11.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart Lyon: International agency for research on cancer. J Thorac Oncol. 2015;10(9):1240–2.PubMedCrossRef
12.
Amin MB, Greene FL, Byrd DR, Edge SB, Compton CC, Gershenwald JE, et al. American joint committee on cancer (AJCC) cancer staging manual. 8th ed. New York: Springer; 2016. p. 1–1024.
13.
14.
Barnes H, See K, Barnett S, Manser R. Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev. 2017;4(4):CD011917.PubMed
15.
Verma V, Simone CB 2nd, Allen PK, Lin SH. Outcomes of stereotactic body radiotherapy for T1–T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: a multicenter analysis. Clin Lung Cancer. 2017;18(6):675-681.e1.PubMedPubMedCentralCrossRef
16.
Yang Y, Zhang D, Zhou X, Bao W, Ji Y, Sheng L, et al. Prophylactic cranial irradiation in resected small cell lung cancer: a systematic review with meta-analysis. J Cancer. 2018;9(2):433–9.PubMedPubMedCentralCrossRef
17.
Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71.PubMedCrossRef
18.
Mascaux C, Paesmans M, Berghmans T, Branlen F, Lafitte JJ, Lemaitre F, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30(1):23–36.PubMedCrossRef
19.
Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8.PubMedCrossRef
20.
Veslemes M, Polyzos A, Latsi P, Dimitroulis J, Stamatiadis D, Dardoufas C, et al. Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide. J Chemother. 1998;10(2):136–40.PubMedCrossRef
21.
Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Tuchais C, et al. Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer. N Engl J Med. 1993;329:1848–52.PubMedCrossRef
22.
De Ruysscher D, Lueza B, Le Pechoux C, Johnson DH, O’Brien M, Murray N, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27(10):1818–28.PubMedPubMedCentralCrossRef
23.
Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol. 2013;24(8):2088–92.PubMedCrossRef
24.
Dingemans AC, Fruh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(). Ann Oncol. 2021;32(7):839–53.PubMedCrossRef
25.
Colaco R, Sheikh H, Lorigan P, Blackhall F, Hulse P, Califano R, et al. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer–evidence from a phase II trial. Lung Cancer. 2012;76(1):72–7.PubMedCrossRef
26.
Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med. 1999;341(7):476–84.PubMedCrossRef
27.
Le Pechoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99–01, EORTC 22003–08004, RTOG 0212, and IFCT 99–01): a randomised clinical trial. Lancet Oncol. 2009;10(5):467–74.PubMedCrossRef
28.
Belderbos JSA, De Ruysscher DKM, De Jaeger K, Koppe F, Lambrecht MLF, Lievens YN, et al. Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675). J Thorac Oncol. 2021;16(5):840–9.PubMedCrossRef
29.
de Dios NR, Counago F, Murcia-Mejia M, Rico-Oses M, Calvo-Crespo P, Samper P, et al. Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): a GICOR-GOECP-SEOR study. J Clin Oncol. 2021;39(28):3118–27.CrossRef
30.
Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, ETOP/IFCT 4-12 STIMULI Collaborators, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy—results from the randomised phase II ETOP/IFCT 4–12 STIMULI trial. Ann Oncol. 2022;33(1):67–79.PubMedCrossRef
31.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, IMpower133 Study Group, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9.PubMedCrossRef
32.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, CASPIAN investigators, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(1):1929–39.PubMedCrossRef
33.
Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, KEYNOTE-604 Investigators, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369–79.PubMedPubMedCentralCrossRef
34.
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of First-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223–32.PubMedPubMedCentralCrossRef
35.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, CAPSTONE-1 Study Group, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–47.PubMedCrossRef
36.
Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999;17(7):2092–9.PubMedCrossRef
37.
Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42.PubMedCrossRef
38.
Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the phase III CREST trial. Lung Cancer. 2017;108:150–3.PubMedCrossRef
39.
Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer. 2016;17(4):239–44.PubMedCrossRef
40.
Rathod S, Jeremic B, Dubey A, Giuliani M, Bashir B, Chowdhury A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Eur J Cancer. 2019;110:110–9.PubMedCrossRef
41.
Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–72.PubMedCrossRef
42.
Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–71.PubMedCrossRef
43.
Bernhardt D, Bozorgmehr F, Adeberg S, Opfermann N, von Eiff D, Rieber J, et al. Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation. Lung Cancer. 2016;101:76–81.PubMedCrossRef
44.
Wegner RE, Olson AC, Kondziolka D, Niranjan A, Lundsford LD, Flickinger JC. Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(3):e21–7.PubMedCrossRef
45.
Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, et al. Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: the FIRE-SCLC Cohort Study. JAMA Oncol. 2020;6(7):1028–37.PubMedPubMedCentralCrossRef
46.
Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7(5):866–72.PubMedPubMedCentralCrossRef
47.
O’Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, Čučeviá B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441–7.PubMedCrossRef
48.
von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–67.CrossRef
49.
Zugazagoitia J, Paz-ares L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol. 2022;40(6):671–81.PubMedCrossRef
50.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645–54.PubMedCrossRef
51.
Paz-Ares L, Ciuleanu T, Navarro A, Fulop A, Cousin S, Bonanno L, et al. PL02.03 lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: phase III randomized ATLANTIS Trial. J Thorac Oncol. 2021;16(10):S844–5.CrossRef
52.
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–95.PubMedCrossRef
53.
Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618–27.PubMedCrossRef
54.
Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol. 2021;32(5):631–41.PubMedCrossRef
55.
Paz Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a first-in-class DLL3-targeted biespecific T-Cell engager, in recurrent small cell lung cancer: an open-label phase I study. J Clin Oncol. 2023;23:J2202823.
56.
Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36:2386–94.PubMedPubMedCentralCrossRef
57.
Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9(10):1372–87.PubMedPubMedCentralCrossRef
58.
Doi T, Patel M, Falchook GS, Koyama T, Friedman CF, Piha-Poul S, et al. DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: extended follow-up of a phase I/II study. Ann Oncol. 2022;33(suppl_7):S197–224.
59.
Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, et al. Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial. J Thorac Oncol. 2019;14(1):63–71.PubMedPubMedCentralCrossRef
60.
Hu X, Bao Y, Jin XY, Neng ZH, Shi LJ, Zhang L, et al. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. Cancer. 2020;126(4):840–9.PubMedCrossRef
61.
Weiss J, Goldschmidt J, Andric Z, Dragnev KH, Gwaltney C, Skaltsa K, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;22(5):449–60.PubMedCrossRef
Metadata
Title
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
Authors
Rosario García-Campelo
Ivana Sullivan
Edurne Arriola
Amelia Insa
Oscar Juan Vidal
Patricia Cruz-Castellanos
Teresa Morán
Noemí Reguart
Jon Zugazagoitia
Manuel Dómine
Publication date
07-07-2023
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2023
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-023-03216-3

Other articles of this Issue 9/2023

Clinical and Translational Oncology 9/2023 Go to the issue

CLINICAL GUIDES IN ONCOLOGY

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

Correction

Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

CLINICAL GUIDES IN ONCOLOGY

SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

EDITORIAL

SEOM 2022 clinical guidelines

Correction

Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

CLINICAL GUIDES IN ONCOLOGY

SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits